Navigation Links
Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference
Date:1/4/2012

PALO ALTO, Calif., Jan. 4, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate update at the 5th Annual OneMedForum Conference on Wednesday, January 11 at 12:00 p.m. Pacific time (3:00 p.m. Eastern time) in San Francisco.  A live and archived webcast of the presentation will be available on the Telik website, www.telik.com.  The archived broadcast of the presentation can be accessed for 30 days following the presentation.

About Telik
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome
2. Telik Announces Presentation and Webcast at 12th Annual BIO CEO & Investor Conference
3. Telik Announces Second Quarter 2009 Financial Results
4. Telik Reports Preclinical Results at AACR Annual Meeting
5. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
6. Telik Announces New TRAP Drug Discovery Agreement
7. Telik Announces Financial Results for 2008 Third Quarter
8. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
9. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
10. Telik Announces Receipt of Nasdaq Notice
11. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):